© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 7, 574-575,
April 5, 2000
© 2000 Oxford University Press
CORRESPONDENCE |
Re: Risk/Benefit Assessment of Tamoxifen to Prevent Breast CancerStill a Work in Progress?
Affiliations of authors: M. H. Gail (Division of Cancer Epidemiology and Genetics). R. Croyle (Division of Cancer Controland Population Science), National Cancer Institute, Bethesda, MD; J. P. Costantino, J. Bryant,University of Pittsburgh, PA; L. Freedman, Bar Illan University, Ramat Gan, Israel; K. Helzlsouer,The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; V. Vogel, University ofPittsburgh Cancer Institute/Magee Women's Hospital.
Correspondence to: Mitchell H. Gail, M.D., Ph.D., National Institutes of Health, Executive Plaza South, Rm. 8032, Bethesda, MD 20892 (gailm@exchange.nih.gov).
We agree with the main contention of the editorial by Taylor et al. (1) that risk/benefit assessments of tamoxifen are very uncertain in black women and other minorities, a point repeatedly stressed by Gail et al. (2). We did want to clarify
NOTE
REFERENCES